Depression treatment for Boynton Beach — measurement-based, 12 minutes away.

RECO Health's Delray Beach campus is a twelve-minute drive south of Renaissance Commons — close enough that Boynton Beach residents can attend PHP or IOP for major depression without displacing work or family. Every plan begins with a DSM-5-TR formulation and baseline PHQ-9, sequences pharmacology by evidence rather than habit, and stages treatment-resistant cases toward rTMS, IV ketamine, or esketamine on a defined schedule instead of a fifth antidepressant trial.

Boynton Beach sits about seven miles north of RECO Health’s Delray Beach campus along Federal Highway — a twelve-minute drive south for residents in Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, or Briny Breezes. For patients considering PHP- or IOP-level care for major depressive disorder, that distance is shorter than most cross-town errands in Boynton itself, which means an intensive treatment schedule can be structured around an existing job, family, or school week rather than displacing it. What follows describes how depression is actually treated here — from the intake formulation through pharmacology, therapy, and, when clinically indicated, interventional escalation.

Diagnostic formulation and severity staging

Every admission for depression begins with a full DSM-5-TR diagnostic formulation rather than a screening checklist. Clinicians differentiate major depressive disorder from persistent depressive disorder (dysthymia), bipolar II depression, adjustment disorder with depressed mood, premenstrual dysphoric disorder, and depression secondary to a general medical condition or substance use. Missing bipolarity — particularly bipolar II — is the most common upstream error in outpatient depression care, so a MDQ screen and a longitudinal mood history precede any antidepressant recommendation.

Severity is anchored by the PHQ-9, with the GAD-7 tracked in parallel because anxious depression responds differently to first-line agents than melancholic presentations. Suicide risk is captured with the C-SSRS at intake and repeated weekly. Baseline labs — TSH, free T4, B12, folate, vitamin D, CMP, and, where clinically indicated, testosterone and inflammatory markers — are reviewed to rule out medical contributors that no antidepressant will correct.

Level of care follows severity, not scheduling convenience. PHP is indicated for severe, acutely suicidal, or functionally collapsed presentations; IOP is appropriate for moderate depression with intact daily functioning; step-down to standard outpatient is planned once the PHQ-9 sits below 10 for a sustained interval and the C-SSRS shows no active ideation.

Pharmacology sequenced by evidence, not habit

First-line pharmacotherapy is an SSRI (sertraline, escitalopram) or an SNRI (venlafaxine, duloxetine), titrated to a therapeutic dose with a four- to six-week response window before the trial is called adequate. Sub-therapeutic doses held for months are the most common reason patients arrive labeled “treatment-resistant” when they are, in fact, undertreated. Bupropion is preferred where sexual side effects or fatigue dominate the target profile; mirtazapine is preferred where insomnia and appetite loss are prominent.

Partial responders are augmented before they are switched. Aripiprazole (2–5 mg), lithium titrated to a level of 0.6–0.8 mEq/L, and bupropion added to an SSRI each carry Level 1 evidence for augmentation of partial response. Quetiapine XR is considered where insomnia and rumination remain refractory. Buspirone augmentation, thyroid augmentation with T3, and low-dose olanzapine combined with fluoxetine remain available second-tier options where they are clinically warranted.

Every medication change is documented alongside the PHQ-9 trajectory, so the decision to switch, augment, or escalate is made from measured data. Treatment-resistant depression is defined operationally as two failed adequate trials of antidepressants from different classes — and TRD patients are staged toward interventional treatment rather than cycled through a fifth oral agent.

Depression-specific behavioral therapy, run to protocol

Cognitive Behavioral Therapy for depression targets cognitive distortions — catastrophizing, personalization, all-or-nothing thinking — and the behavioral withdrawal that maintains anhedonia. Behavioral Activation runs as its own manualized protocol, restoring rewarding and mastery activities on a graded weekly schedule; evidence supports BA as non-inferior to full-course CBT for many patients and it is often the higher-yield opening move when psychomotor slowing is prominent. Interpersonal Therapy is chosen where grief, role transition, or relational conflict is the identified depression driver rather than pure cognitive-behavioral pathology.

For clients whose depression is trauma-linked — a common overlap in this population — Cognitive Processing Therapy or EMDR is layered in once affect regulation is stable. ACT is used with clients whose depression sits on top of chronic pain, chronic medical illness, or a sustained values disconnection. Motivational Interviewing is embedded throughout for ambivalence about medication adherence, group attendance, or lifestyle change.

Group programming at PHP and IOP includes a psychoeducation track, a skills track (behavioral activation planning, cognitive restructuring, sleep and circadian regulation, DBT distress tolerance), and process groups, all facilitated by masters-level or doctoral clinicians rather than peer volunteers.

Escalation pathway when medication and therapy aren’t enough

Roughly a third of patients with major depression will not reach remission after two adequate antidepressant trials. The escalation pathway is therefore defined in advance rather than improvised. rTMS is offered on the standard 10 Hz left DLPFC protocol — 3,000 pulses per session at 120% of resting motor threshold, delivered over a 36-session course — for TRD patients whose insurance authorizes the intervention and who prefer a non-systemic option with a benign side-effect profile.

IV ketamine (0.5 mg/kg over 40 minutes, six-infusion induction across two to three weeks) is used where rapid response is clinically necessary — acute suicidality, functional collapse, or a caregiver situation that will not tolerate a six-week oral medication trial. Response is measured with the PHQ-9 at each infusion and maintenance decisions are made from that trajectory rather than a default cadence.

Esketamine (Spravato) is available where a REMS-monitored intranasal protocol is preferred by patient or payer. Referral for ECT is arranged with a hospital partner where catatonic features, severe psychotic depression, or contraindications to other interventional options are present. Patients researching this pathway can review the full depression treatment program before calling.

What the first 72 hours look like

The initial evaluation is a 90-minute intake with a licensed clinician and, when clinically indicated same-day, a psychiatric provider. It includes the DSM-5-TR formulation, PHQ-9, GAD-7, C-SSRS, a MDQ if any hypomanic history is elicited, an ASRS if adult attention concerns are present, and an AUDIT-C plus DAST-10 to characterize any substance involvement. Prior psychiatric records and current medication lists are requested during intake rather than weeks later.

Within 72 hours, a written treatment plan is finalized: specific pharmacology decisions with target doses and review dates, therapy modality assignments, group schedule, and — where relevant — a rTMS or ketamine consultation appointment. Family contact and release-of-information decisions are made deliberately with the patient rather than defaulted in either direction.

Insurance and admissions from Boynton Beach

RECO Health is in-network with major commercial payers including Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans. Verification of benefits is completed before admission so the level of care recommendation and the coverage available are matched at intake — not discovered mid-treatment or contested after a discharge summary is submitted.

For Boynton Beach residents, the practical logistics are minimal: I-95 or Federal Highway south for roughly twelve minutes to the Delray Beach campus. Transportation coordination is available for PHP patients where driving is contraindicated by medication initiation, ketamine infusion recovery windows, or symptom severity. Employer FMLA paperwork and short-term disability documentation are prepared by the treating psychiatrist as part of the standard clinical workflow rather than handed to the patient.

Serving residents of: Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, Briny Breezes.